ODAIA Raises US$15 million Series C to Grow Pharma Accounts and Develop Commercial Intelligence Platform

ODAIA has closed a US$15 million Series C led by Monograph Capital and anchored by strategic investor PHM, part of Publicis Groupe. The financing will support growth within existing enterprise pharma accounts and continued innovation of its commercial intelligence platform.
- Raised
- US$15 million
- Round
- Series C
- Investors
- 8
- Investors
- Monograph CapitalPHMBDC CapitalFlint CapitalInnospark VenturesGraphite VenturesThreshold VenturesWittington Ventures
- Target market
- Enterprise pharma commercial teams
- Use of funds
- Growing within existing enterprise pharma accounts, continuing platform innovation and bringing the platform to more pharma teams
Get started
Create a free account to read the full story.
Quick Answers
What is the latest news about ODAIA?
ODAIA has closed a US$15 million Series C led by Monograph Capital and anchored by strategic investor PHM, part of Publicis Groupe. The financing will support growth within existing enterprise pharma accounts and continued innovation of its commercial intelligence platform.
What does ODAIA do?
ODAIA provides AI-powered predictive commercial intelligence for pharma. Its customers include four of the top 15 global biopharmaceutical organizations.
How much did ODAIA raise?
ODAIA raised US$15 million in its Series C.
Who invested in ODAIA?
Investors named in this Series C include Monograph Capital, PHM, BDC Capital, Flint Capital, Innospark Ventures, Graphite Ventures, Threshold Ventures and Wittington Ventures.
How will ODAIA use the funding?
ODAIA plans to use the money for growing within existing enterprise pharma accounts, continuing platform innovation and bringing the platform to more pharma teams.
Where is ODAIA based?
ODAIA is based in Canada.
Who are the key people at ODAIA?
Key people named in this report: Philip Poulidis (CEO & CoFounder) and Zak Beharie (CTO).
